Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

The newly launched biotech is equipped with rights to a trio of weight loss medicines licensed from China-based Sciwind ...

F45 Training Holdings Inc., a leading global fitness community known for innovative, high-energy group workouts, announced ...

Madrigal Pharmaceuticals' strong launch is confirmed with impressive sales in Q1 and Q2. Learn why MDGL stock could benefit ...

Scholar Rock , a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Verdiva Bio Limited ("Verdiva" or "the Company") today announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other ...

New analysis from GlobalData spans the growth of the heart failure market across seven major markets including the US, Europe ...

Industry leaders share their thoughts and concerns about the health care landscape and how it will affect their 2025.

The global biotechnology industry market size is projected to expand from USD 483.0 billion in 2024 to USD 546.0 billion by 2025, reflecting ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

Antiobesity drugs are amazing people by how fast they melt off pounds. But it's no surprise to Richard DiMarchi.